Using Combination Therapy as Treatment of Non-Clear Cell RCC

Systemic treatment options for patients with nccRCCПодробнее

Advanced Non-Clear Cell Renal Cell CarcinomaПодробнее

2024 KCA Virtual Patient Symposium: How Doctors Decide How To Treat Your CancerПодробнее

Management Round-Up: Translocation, Chromophobe, RMC, and Other SubtypesПодробнее

KCRS24 Session Five: Clinical and Scientific Updates in Kidney Cancer | KidneyCANПодробнее

Managing Metastatic nccRCC: Historical Approaches and Current ChangesПодробнее

Evolution of Combination Therapy in nccRCC, Papillary SubtypeПодробнее

Future Directions in nccRCC: SAMETA, FORTUNE, and Second-Line TreatmentПодробнее

IO/TKI and PD-L1 Approaches, Trials in nccRCCПодробнее

Adjuvant Setting, Toxicity Considerations for Single-Agent, Combination nccRCC TherapyПодробнее

Promising TKI-ICI combinations for non-clear cell RCCПодробнее

Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023Подробнее

The challenges and potential of triple therapies in non-clear cell RCCПодробнее

Advanced Kidney Cancer: What the Urologist Needs to KnowПодробнее

Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma:Подробнее

UROwebinar: Management of Metastatic kidney cancerПодробнее

KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCCПодробнее

Clearing Up Non-Clear Cell Renal Cell Carcinoma ManagementПодробнее

Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationaleПодробнее

Kidney Cancer Conference Highlights from ASCO 2023Подробнее